---
title: "Eli Lilly (LLY) stock news, pipeline, cash and catalysts"
url: "https://aibio.space/companies/eli-lilly/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "Eli Lilly news for investors: Eli Lilly is a U.S. drugmaker whose sales are led by the diabetes and obesity drugs Mounjaro and Zepbound, with businesses in…"
---

Desk view · Opinion · Updated Oct 22, 2026

## Lilly's growth is real; price, debt and retatrutide's label are the tests

Lilly is the volume leader in obesity drugs and its next products, Foundayo and retatrutide, are approved or late-stage. The risks are falling net prices, rising debt and the safety profile retatrutide will carry onto its label.

Read the full desk view

aibio.space Investor Rank · Opinion

**9** /10 Most positive view

The obesity volume leader, with tirzepatide sales surging and follow-on drugs approved or late stage; falling net prices, rising debt and retatrutide's label are the watch points.

- **Technology**: 2/2

- **Odds**: 2/2

- **Balance sheet**: 1/2

- **Risk**: 2/2

- **Momentum**: 2/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank).

- **Technology**: **Proven at scale.** Tirzepatide drives about 65% of Q2 revenue, and the oral Foundayo pill is approved for obesity.

- **Odds**: **High for the late-stage book.** Retatrutide has a complete phase 3 package; filings to approval succeed about 90.6% of the time in industry data.

- **Balance sheet**: **Profitable but more leveraged.** Cash of $8.95 billion at June 30 against about $55 billion of total debt after a deal-heavy year.

- **Main risk**: **Net price erosion.** Realized prices fell 13% in Q2 as Lilly widened access and competition with Novo Nordisk intensified.

- **Watch next**: **Q3 results on October 29.** Guidance, Foundayo uptake and any deal charges are the numbers to watch.

## Top news on Eli

1. 2026-08-13 Distress [Sangamo bankruptcy auction brings in $163.55 million from PTC and Lilly](https://aibio.space/news/sangamo-bankruptcy-auction-brings-163-55-million-ptc-lilly/) Winning bids yield about $163.55 million in cash at closing and up to $100 million in milestones. Every sale still needs court approval, and the company is still selling other assets.
2. 2026-01-08 Financings [Aktis Oncology prices upsized IPO at $18, raising about $318 million](https://aibio.space/news/aktis-oncology-prices-upsized-ipo-18-raising-about-318-million/) The radiopharmaceutical developer sold 17.65 million shares on the Nasdaq, the first U.S. biotech IPO of 2026, after raising its offering size.

## Dates

**October 29, 2026**
Third-quarter 2026 financial results and conference call [Source](https://lilly.gcs-web.com/news-releases/news-release-details/lilly-confirms-date-and-conference-call-third-quarter-2026)

**Q1 2027**
Planned U.S. Biologics License Application for retatrutide [Source](https://lilly.gcs-web.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional)

**Not dated**
FDA decision on Foundayo for type 2 diabetes (submitted) [Source](https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm)

## The money

Cash and cash equivalents of $8.95 billion at June 30, 2026 (Q2), against $47.86 billion of noncurrent long-term debt and $7.05 billion of current debt. No runway guidance applies; the company is profitable. [Source](https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm)

Q2 2026 revenue of $22.97 billion, up 48%; Mounjaro $9.94 billion, Zepbound $4.93 billion, Foundayo $98 million. 2026 guidance raised to $85 billion to $87 billion. [Source](https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm)

## Risks on the record

- Realized prices fell 13% in Q2 2026; revenue growth depends on volume outpacing price declines. [Source](https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm)
- Noncurrent long-term debt rose from $40.87 billion at Dec. 31, 2025 to $47.86 billion at June 30, 2026 while the company funded acquisitions and manufacturing. [Source](https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm)
- Retatrutide's TRIUMPH-3 trial did not show a clear cardiovascular benefit and had adverse-event discontinuation rates up to 13.5% versus 4.8% on placebo. [Source](https://lilly.gcs-web.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional)

## Questions investors ask

### What is aibio.space's Investor Rank for Eli Lilly?

9 out of 10, our most positive view. The obesity volume leader, with tirzepatide sales surging and follow-on drugs approved or late stage; falling net prices, rising debt and retatrutide's label are the watch points. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank)

### How much revenue did Eli Lilly make in Q2 2026?

Lilly reported second-quarter 2026 revenue of $22.97 billion, up 48% from a year earlier. Mounjaro brought in $9.94 billion and Zepbound $4.93 billion. [Source](https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm)

### When will Lilly file retatrutide with the FDA?

Lilly plans to submit a Biologics License Application for retatrutide to the FDA in the first quarter of 2027. It is finishing the manufacturing section of the application after three positive phase 3 obesity trials. [Source](https://lilly.gcs-web.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional)

### When was Lilly's weight loss pill Foundayo approved?

The FDA approved Foundayo (orforglipron) for obesity on April 1, 2026, after a 50-day review. Lilly has also submitted it in the U.S. for type 2 diabetes. [Source](https://pbs.org/newshour/health/fda-grants-speedy-approval-to-eli-lillys-weight-loss-pill-for-obesity)

### What did Lilly pay for AtaiBeckley?

Lilly paid $6.75 per share in cash, about $2.8 billion in equity value, plus contingent value rights worth up to $2.50 per share. The deal closed on September 11, 2026. [Source](https://lilly.gcs-web.com/news-releases/news-release-details/lilly-acquire-ataibeckley-advance-therapies-treatment-resistant)

### When does Eli Lilly report Q3 2026 earnings?

Lilly will announce third-quarter 2026 results on October 29, 2026, with a conference call at 10 a.m. Eastern time. [Source](https://lilly.gcs-web.com/news-releases/news-release-details/lilly-confirms-date-and-conference-call-third-quarter-2026)

### What is Eli Lilly's market cap?

We do not publish live share prices. In its annual report, Eli Lilly and Company put the market value of shares held by non-affiliates (public float) at $807.89 billion as of Jun 30, 2025. Source

### Is Eli Lilly a smaller reporting company?

SEC records list Eli Lilly and Company's filer category as: Large accelerated filer. Source

### Where is Eli Lilly headquartered?

SEC records list its business address as LILLY CORPORATE CTR, INDIANAPOLIS, IN, 46285. Source

### When does Eli Lilly's fiscal year end?

Eli Lilly and Company's fiscal year ends on December 31, per SEC records. Source

### What did Eli Lilly last file with the SEC?

Its most recent filing in our record is a 10-Q filed 2026-08-05. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm)

### What was Eli Lilly called before?

SEC records list these former names: LILLY ELI & CO; LILLY ELI & CO ET AL. Source

### What industry is Eli Lilly in?

Its SEC industry code (SIC 2834) is Pharmaceutical Preparations. Source

### Which other companies' news mentions Eli Lilly?

Eli Lilly is named in 2 of our stories about other companies, most recently: "Sangamo bankruptcy auction brings in $163.55 million from PTC and Lilly" (Aug 13, 2026); "Aktis Oncology prices upsized IPO at $18, raising about $318 million" (Jan 8, 2026). [Source](https://aibio.space/news/sangamo-bankruptcy-auction-brings-163-55-million-ptc-lilly/)

### How can I follow Eli Lilly (LLY) news?

Press Follow on this page to add Eli Lilly to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming Eli Lilly so far, in Distress, Financings. Source

## Legal and investor matters

Checked against Eli Lilly filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

Lilly's 10-Q filed 2026-08-05 (Part II, Item 1 and Note 9) says Lilly is a party to various pending legal actions, government investigations and environmental proceedings. Note 9 describes patent, pricing, qui tam, 340B antitrust and product liability matters. It does not describe a securities class action or shareholder derivative suit. [Source](https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm)

1. 2026-08-05 Litigation Generic makers file applications to copy Mounjaro, Zepbound and Verzenio The 10-Q filed 2026-08-05 says Lilly received notice in July 2026 that multiple generic companies had filed abbreviated new drug applications to market generic versions of Mounjaro and/or Zepbound before patent expiry, and that Lilly intends to file suit. In April 2026 Cipla filed an application for generic Verzenio tablets, and in June 2026 Lilly sued Cipla in the District of Delaware. U.S. District Court for the District of Delaware · Status: pending [Lilly Form 10-Q (2026-08-05)](https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm)
2. 2026-08-05 Litigation Michigan Supreme Court reverses ruling for Lilly in insulin investigation case The 10-Q filed 2026-08-05 reports that in July 2026 the Michigan Supreme Court reversed a Michigan Court of Appeals decision that had affirmed a judgment in Lilly's favor. The case concerns whether the Michigan attorney general has authority to investigate Lilly's insulin sales under the Michigan Consumer Protection Act. Separately, the 10-Q says most insulin pricing cases, including putative class actions, have been coordinated or consolidated in a multidistrict litigation in the District of New Jersey. Michigan Supreme Court · Status: appealed [Lilly Form 10-Q (2026-08-05)](https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm)
3. 2026-08-05 Litigation Supreme Court declines review of average manufacturer price verdict against Lilly In November 2014 a relator filed a qui tam action in the Northern District of Illinois against Lilly and Takeda Pharmaceuticals America. The relator's complaint alleged that the defendants should have treated certain distributor credits as retroactive price increases in calculating average manufacturer prices. A jury returned a verdict for the relator in August 2022. The Seventh Circuit affirmed in September 2025, and Lilly recognized a charge. The 10-Q filed 2026-08-05 says the U.S. Supreme Court denied further review in May 2026. U.S. District Court for the Northern District of Illinois [Lilly Form 10-Q (2026-08-05)](https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm)
4. 2026-08-05 Litigation Putative antitrust class action over 340B programs: Lilly petitions Supreme Court In July 2021 Mosaic Health filed a putative class action in the Western District of New York against Lilly, Sanofi, Novo Nordisk and AstraZeneca, alleging antitrust and unjust enrichment claims related to their 340B programs. The district court dismissed the case for failure to state a claim, the Second Circuit reversed, and Lilly filed a petition for Supreme Court review in March 2026. The 10-Q filed 2026-08-05 says the matter is ongoing. It also describes other 340B lawsuits against Lilly and a pending Seventh Circuit appeal. U.S. District Court for the Western District of New York · Status: pending [Lilly Form 10-Q (2026-08-05)](https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm)
5. 2026-05-20 Financing Lilly completes offering of eight series of notes On 2026-05-20 Eli Lilly completed an offering of two series of floating rate notes and six series of fixed rate notes, with maturities from 2028 to 2066. The largest series were $1,750,000,000 of 5.600% Notes due 2056, and $1,500,000,000 each of 4.375% Notes due 2031 and 4.850% Notes due 2036. Lilly disclosed the offering under Item 8.01 of a Form 8-K. [Lilly Form 8-K](https://www.sec.gov/Archives/edgar/data/59478/000119312526232707/d148580d8k.htm)
6. 2026-04-30 Litigation Federal Circuit reverses ruling for Lilly in Teva Emgality patent case Teva sued Lilly in 2018 in the District of Massachusetts, alleging that Emgality infringes three Teva patents. A jury found for Teva in 2022, but the trial court overruled the verdict in 2023 and held the claims invalid. In April 2026 the Federal Circuit reversed that invalidity finding and remanded. Lilly recognized a charge in the first quarter of 2026, and the 10-Q filed 2026-08-05 says Lilly petitioned for rehearing en banc in June 2026. U.S. District Court for the District of Massachusetts; U.S. Court of Appeals for the Federal Circuit · Status: appealed [Lilly Form 10-Q (2026-08-05)](https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm)
7. 2025-08-18 Financing Lilly sells seven series of notes under August 2025 underwriting agreement On 2025-08-18 Eli Lilly entered an underwriting agreement with Citigroup, Goldman Sachs, J.P. Morgan, Mizuho and Morgan Stanley as representatives for the sale of seven series of notes. They include $750,000,000 of floating rate notes due 2028 and $1,000,000,000 each of 4.000% Notes due 2028, 4.550% Notes due 2032, 5.550% Notes due 2055 and 5.650% Notes due 2065. [Lilly Form 8-K](https://www.sec.gov/Archives/edgar/data/59478/000119312525184093/d929636d8k.htm)
8. 2025-02-10 Financing Lilly sells six series of notes under February 2025 underwriting agreement On 2025-02-10 Eli Lilly entered an underwriting agreement with Barclays, BofA Securities, Citigroup, Deutsche Bank and Goldman Sachs as representatives for the sale of six series of notes maturing from 2028 to 2065. The series include $1,250,000,000 each of 4.750% Notes due 2030, 5.100% Notes due 2035 and 5.500% Notes due 2055, and $1,000,000,000 each of 4.550% Notes due 2028 and 4.900% Notes due 2032. [Lilly Form 8-K](https://www.sec.gov/Archives/edgar/data/59478/000119312525025057/d868986d8k.htm)

## Pipeline

| Program | Indication | Stage |
|---|---|---|
| Tirzepatide (Mounjaro, Zepbound) | Type 2 diabetes, obesity | Marketed [Source](https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm) |
| Orforglipron (Foundayo) | Obesity (approved); type 2 diabetes (filed in U.S.) | Marketed / under FDA review [Source](https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm) |
| Retatrutide | Obesity, obstructive sleep apnea, knee osteoarthritis pain | Phase 3 complete; BLA planned Q1 2027 [Source](https://lilly.gcs-web.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional) |
| Pirtobrutinib (Jaypirca) | CLL/SLL, including first line | Marketed; first-line U.S. approval Oct 2026 [Source](https://www.prnewswire.com/news-releases/lillys-jaypirca-pirtobrutinib-the-first-and-only-approved-non-covalent-btk-inhibitor-receives-expanded-indication-from-us-fda-for-certain-patients-with-previously-untreated-cllsll-302897416.html) |
| BPL-003 (mebufotenin benzoate) | Treatment-resistant depression | Phase 3 activities started [Source](https://lilly.gcs-web.com/news-releases/news-release-details/lilly-acquire-ataibeckley-advance-therapies-treatment-resistant) |
| Olomorasib | KRAS G12C-mutant pancreatic cancer (previously treated) | Clinical; FDA Breakthrough Therapy designation [Source](https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm) |

Opinion · Devil's advocate

## Fact-check-o-meter

Consistent

Lilly's releases and its 10-Q tell the same story, and the releases carry most of their own caveats

The Q2 release, the retatrutide release and the Foundayo comparison release match the 10-Q and the trial records where we could check them. The price drop, the acquired R&D charge and the limits of an indirect comparison are all stated in the releases themselves. What a reader of the releases alone would miss is the growth in borrowing and the product liability suits over tirzepatide, which sit in the 10-Q.

1. Press release vs filing · weight low Price erosion is disclosed in both documents **The company said:** "Excluding these adjustments, U.S. price would have declined by approximately 9%." [source](https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm) **The record says:** The 10-Q says U.S. "lower realized prices were primarily driven by Zepbound and Mounjaro, partially offset by adjustments to estimates for rebates and discounts primarily driven by Trulicity, Mounjaro, and Zepbound". [source](https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm) **Our view:** The release leads with 48% revenue growth but states the 13% fall in realized prices and the 9% underlying U.S. decline in the same section. The filing agrees. This is consistent messaging, and the open question is how long volume can outrun price.
2. Press release vs filing · weight low Borrowing growth is in the filing, not the release **The company said:** "Increased 2026 full-year revenue guidance to be in the range of $85.0 billion to $87.0 billion" [source](https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm) **The record says:** The 10-Q balance sheet shows long-term debt of $47,858 million at June 30, 2026 against $40,868 million at December 31, 2025, and short-term borrowings and current maturities of $7,050 million against $1,635 million. The release says the $3.03 per share of acquired IPR&D charges more than offset the raised underlying non-GAAP EPS guidance. [source](https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm) **Our view:** The release is open about the acquired R&D charge but does not discuss the debt that funded the deals. Investors who read only the release would not see the balance sheet change.
3. Science · weight medium Foundayo versus oral semaglutide is an indirect comparison **The company said:** "Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison" [source](https://www.prnewswire.com/news-releases/lillys-foundayo-orforglipron-17-2-mg-showed-greater-weight-loss-and-a1c-reduction-than-oral-semaglutide-25-mg-among-adults-with-type-2-diabetes-in-a-new-indirect-treatment-comparison-302891494.html) **The record says:** ClinicalTrials.gov lists ACHIEVE-3 (NCT06045221) with masking "NONE", and the release itself calls it "open-label". The release says "A 25 mg once-daily dose of oral semaglutide is not approved in the United States for the treatment of type 2 diabetes" and that data use the efficacy estimand. The weight-loss gain was 1.5% with a 95% CI of -2.7% to -0.2%. The registry lists orforglipron doses of 12 mg and 36 mg, while the release uses 9 mg and 17.2 mg, and the release does not explain the labels. [source](https://clinicaltrials.gov/study/NCT06045221) **Our view:** The headline is accurate, and the release's own quote from a Lilly executive says Foundayo "may deliver A1C and weight lowering that is similar to the 25 mg dose". An adjusted cross-trial comparison with a wide interval is weaker evidence than the headline suggests.
4. Science · weight medium Retatrutide: weight loss met, cardiovascular benefit not shown **The company said:** "major adverse cardiovascular events (MACE) occurred less frequently than anticipated in both retatrutide and placebo arms" [source](https://lilly.gcs-web.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional) **The record says:** The release reports "Discontinuation rates due to adverse events in TRIUMPH-3 were 9.8% (9 mg) and 13.5% (12 mg)." Placebo was 4.8%. The release also reports a MACE-3 hazard ratio of 1.12 (95.0% CI: 0.64 to 1.96) for pooled retatrutide against placebo. ClinicalTrials.gov lists the TRIUMPH-3 primary outcome (NCT05882045) as percent change in body weight at week 80, double-masked, with 1,946 actual participants. [source](https://clinicaltrials.gov/study/NCT05882045) **Our view:** The release does not claim a cardiovascular benefit and gives the discontinuation rates, so there is no gap with the record. The trial was sized and designed for weight loss, and the higher dropout on drug is the number to watch when the BLA is filed.
5. Legal and disclosure record · weight medium Tirzepatide product liability MDLs and generic filings disclosed **The record says:** Note 9 of the 10-Q: "Most of these lawsuits in the United States have been coordinated or consolidated for pretrial proceedings in two federal MDLs: one focused on alleged gastrointestinal injuries, and the other relating to claims of non-arteritic anterior ischemic optic neuropathy (NAION). Both MDLs are pending in the U.S. District Court for the Eastern District of Pennsylvania." It also says "In July 2026, Lilly received notice that multiple generic companies had filed ANDAs seeking approval to market generic versions of Mounjaro and/or Zepbound". [source](https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm) **Our view:** These are matters Lilly discloses itself. The litigation note does not describe a securities class action, and the Q2 release does not mention the product liability MDLs or the generic filings.

Documents we compared

- [Lilly Q2 2026 results release (8-K Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm) 2026-08-05
- [Lilly Form 10-Q for the quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm) 2026-08-05
- [Lilly retatrutide TRIUMPH-2 and TRIUMPH-3 release](https://lilly.gcs-web.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional) 2026-07-23
- [Lilly Foundayo indirect treatment comparison release](https://www.prnewswire.com/news-releases/lillys-foundayo-orforglipron-17-2-mg-showed-greater-weight-loss-and-a1c-reduction-than-oral-semaglutide-25-mg-among-adults-with-type-2-diabetes-in-a-new-indirect-treatment-comparison-302891494.html) 2026-09-29
- [ClinicalTrials.gov NCT06045221 (ACHIEVE-3)](https://clinicaltrials.gov/study/NCT06045221) 2026-09-15
- [ClinicalTrials.gov NCT05882045 (TRIUMPH-3)](https://clinicaltrials.gov/study/NCT05882045) 2026-07-30

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply).

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NYSE:LLY on TradingView](https://www.tradingview.com/symbols/NYSE-LLY/).

## SEC filings and registration

- **SEC name**: ELI LILLY & Co

- **CIK**: 59478

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: LLY (NYSE)

- **State or country of incorporation**: IN

- **Fiscal year ends**: December 31

- **Filer category**: Large accelerated filer

- **Business address**: LILLY CORPORATE CTR, INDIANAPOLIS, IN, 46285

- **Phone**: 3172762000

- **Shares outstanding**: 941,357,065 as of 2026-08-03 (10-Q filed 2026-08-05)

- **Former names**: LILLY ELI & CO; LILLY ELI & CO ET AL

### Recent filings (8-K and 6-K are the company's own announcements)

- [10-Q](https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm) filed 2026-08-05
- [8-K](https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/lly-20260805.htm) filed 2026-08-05
- [8-K](https://www.sec.gov/Archives/edgar/data/59478/000119312526232707/d148580d8k.htm) filed 2026-05-20
- [8-K](https://www.sec.gov/Archives/edgar/data/59478/000005947826000048/lly-20260504.htm) filed 2026-05-07
- [10-Q](https://www.sec.gov/Archives/edgar/data/59478/000005947826000045/lly-20260331.htm) filed 2026-04-30
- [8-K](https://www.sec.gov/Archives/edgar/data/59478/000005947826000043/lly-20260430.htm) filed 2026-04-30
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/59478/000005947826000029/lly-20260317.htm) filed 2026-03-20
- [10-K](https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm) filed 2026-02-12

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/eli-lilly/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Eli Lilly (LLY) stock news, pipeline, cash and catalysts", 2026-10-31, https://aibio.space/companies/eli-lilly/